Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
European Journal of Rheumatology|September 23, 2020
Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritisKathleen Tymms, Belinda Butcher, Tegan Smith, et al.
Clinical and Experimental Rheumatology|December 11, 2019
Using big data from real-world Australian rheumatology encounters to enhance clinical care and researchGeoffrey O Littlejohn, Kathleen E Tymms, Tegan Smith, et al.
Clinical Rheumatology|July 5, 2023
Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL datasetSabina Ciciriello, Geoffrey Littlejohn, Catherine O'Sullivan, et al.
Clinical Rheumatology|August 9, 2021
Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in AustraliaPaul Bird, Geoffrey Littlejohn, Belinda Butcher, et al.
The Journal of Rheumatology|August 2, 2021
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL DatasetHedley Griffiths, Tegan Smith, Christopher Mack, et al.
Clinical Rheumatology|April 18, 2024
Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022Geoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
Clinical Rheumatology|March 12, 2020
Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in AustraliaPaul Bird, Geoffrey Littlejohn, Belinda Butcher, et al.
Internal Medicine Journal|November 27, 2023
Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savingsClaire T Deakin, Geoffrey O Littlejohn, Hedley Griffiths, et al.
Rheumatology and Therapy|January 5, 2025
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
Clinical Rheumatology|March 8, 2024
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in AustraliaGeoffrey Littlejohn, Joanna Leadbetter, Belinda E Butcher, et al.
Pageof 2